Effects of linoleic and oleic acid anilides on prostacyclin synthesis and fibrinolytic profile of human endothelial cells in culture: relevance to the toxic oil syndrome.
We evaluated the effects of fatty-acid anilides (FAA) on prostacyclin (PGI2) synthesis and on the fibrinolytic properties of human umbilical vein endothelial cells. Preincubation of endothelial cells with oleic- and linoleic-anilides (OAA and LAA, respectively) resulted in a time- and concentration-dependent inhibition of ionophore A23187- and thrombin-induced PGI2 synthesis. However, no significant effects of FAA on arachidonic acid-induced PGI2 synthesis were found, except with 1000 microM LAA which inhibited cyclooxygenase activity after 24 h. In general terms, OAA showed similar inhibitory effects on PGI2 production as did LAA, but with a shifted time course, since the production of PGI2 at 24 h for OAA was similar to that observed for LAA at 2 h. The release of labeled arachidonic acid from cell membranes was significantly reduced (75-85%), after 24 h, with both FAA. The effect of 100 microM LAA on thrombin-induced PGI2 production was rapid (within 15 min) and irreversible after 60 min. The recovery of PGI2 synthesis after LAA treatment was blocked by cycloheximide, suggesting a decrease of phospholipase(s) activity or cessation of enzyme synthesis. Moreover, this reduced PGI2 synthesis was not associated with [3H]adenine release. Our data indicate that FAA induce a significant impairment of stimulated PGI2 synthesis and arachidonic acid release in endothelial cells, acting primarily as inhibitors of phospholipase(s) rather than of cyclooxygenase. Finally, both LAA and OAA induce an anti-fibrinolytic activity in these cells where major changes are observed in the plasminogen activator inhibitor and the urine-type plasminogen activator.
de Castellarnau
C
C
Atherothrombosis-Vascular Biology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain.
Pich
I
I
Chanquia
C
C
Vila
L
L
Lagunas
C
C
Fontcuberta
J
J
Rutllant
M
M
D000813:Anilides / Q000494:pharmacology*; D016718:Arachidonic Acid / Q000378:metabolism; D001937:Brassica; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000187:drug effects*; D011464:Epoprostenol / Q000096:biosynthesis*; D005229:Fatty Acids, Monounsaturated; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D008041:Linoleic Acids / Q000494:pharmacology*; D009829:Oleic Acids / Q000494:pharmacology*; D010938:Plant Oils / Q000506:poisoning; D000074262:Rapeseed Oil
D000813:Anilides; D005229:Fatty Acids, Monounsaturated; D008041:Linoleic Acids; D009829:Oleic Acids; D010938:Plant Oils; D000074262:Rapeseed Oil; C039294:linoleylanilide; D016718:Arachidonic Acid; C038731:oleoylanilide; D011464:Epoprostenol